What is Manganese Glycerophosphate?
Manganese glycerophosphate is an organic salt formed by combining manganese with glycerophosphoric acid. The compound has the CAS number 1320-46-3 and belongs to the category of nutrient supplements. It functions as a source of bioavailable manganese, a trace mineral essential for human health and physiological processes.
The glycerophosphate form is designed to enhance absorption and bioavailability compared to other manganese compounds. This chelation approach allows the mineral to be more readily utilized by the body, making it an attractive option for food fortification applications.
Common Uses
Manganese glycerophosphate is used primarily as a nutrient fortification agent in food and beverage products. It appears in nutritional supplements, fortified cereals, plant-based milk alternatives, and other functional foods designed to address potential manganese deficiency. The compound is particularly relevant in formulations targeting populations at risk of inadequate manganese intake, including those following restrictive diets.
The nutrient supplement category encompasses ingredients that add nutritional value to food products, and manganese glycerophosphate serves this purpose by providing a source of essential trace minerals. Its use is most common in North America and Europe where fortification practices are well-established.
Safety Assessment
Manganese glycerophosphate has generated zero reported adverse events in FDA databases and has no associated product recalls. These records indicate no safety signals from consumer use or reported incidents of harm in the United States food supply.
Manganese itself is an essential micronutrient recognized by health organizations worldwide. The FDA established adequate intake levels for manganese at 1.8 mg/day for adult women and 2.3 mg/day for adult men. Toxicity from manganese consumed through food sources is rare, though excessive supplemental intake has been studied in occupational exposure and high-dose supplement contexts.
The glycerophosphate carrier compound is generally recognized as safe when used in food applications. Glycerophosphoric acid derivatives have been used in food fortification for decades without significant safety concerns at typical use levels.
Regulatory Status
Manganese glycerophosphate is not listed as GRAS (Generally Recognized as Safe) by the FDA under Title 21 of the Code of Federal Regulations. However, this designation does not indicate a safety concern; rather, it reflects that the specific compound has not undergone formal GRAS petition review or that manufacturers have not sought this designation.
The ingredient is permitted in some food fortification applications in the United States under FDA regulations governing nutrient supplements and fortified foods. Its regulatory status varies internationally, with approval in certain European and Asian markets. The European Food Safety Authority (EFSA) has not issued specific guidance on manganese glycerophosphate, though it recognizes manganese as an essential nutrient suitable for fortification.
Manufacturers using this ingredient must comply with labeling regulations, proper identification, and permitted use levels in specific food categories.
Key Studies
Limited published literature specifically addresses manganese glycerophosphate efficacy and safety. Most research focuses on manganese bioavailability in general and the benefits of organic manganese complexes compared to inorganic salts.
Research on chelated mineral compounds demonstrates that organic acid complexes like glycerophosphates can enhance mineral absorption. Studies on manganese nutrition support the importance of adequate intake for bone health, glucose metabolism, and antioxidant defense through manganese-dependent enzymes such as manganese superoxide dismutase.
The absence of adverse event reports and recalls in FDA databases, combined with the established safety of manganese as a nutrient and glycerophosphate as a food component, provides empirical support for safety at permitted use levels. However, comprehensive human clinical trials specifically evaluating manganese glycerophosphate remain limited in published literature.